Meeting
2023 ASCO Annual Meeting
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.
Authors
Benjamin M. Ellingson
University of California Los Angeles, Los Angeles, CA
Benjamin M. Ellingson , Akifumi Hagiwara , Connor Morris , Nicholas Cho , Sonoko Oshima , Francesco Sanvito , Talia Oughourlian , Catalina Raymond , Lauren E. Abrey , Josep Garcia , Dana T. Aftab , Colin Hessel , Tamar Rachmilewitz Minei , Shifra Fain Shmueli , David Nathanson , Patrick Y. Wen , Timothy Francis Cloughesy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT00345163; NCT00704288; NCT02511405
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2063)
DOI
10.1200/JCO.2023.41.16_suppl.2063
Abstract #
2063
Poster Bd #
420
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy.
First Author: Benjamin M. Ellingson
Poster
2016 ASCO Annual Meeting
Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.
First Author: Aurelie Bertaut
Poster
2023 ASCO Annual Meeting
Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).
First Author: Samuel Aaron Goldlust
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of atezolizumab/bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma (HCC) according to the type of disease progression.
First Author: Spyridon Pantzios